PDF
(Download)
|
- Saw Palmetto (Serenoa repens)
- Benign Prostatic Hyperplasia
- Dosage
| Date:
11-30-2011 | HC#
111151-437
|
Re: Symptoms of Benign Prostatic Hyperplasia Unaffected by High Doses of Saw Palmetto Ethanolic Extract
Barry
MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract
on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344-1351.
Benign
prostatic hyperplasia (BPH)—enlargement of the prostate—causes lower urinary
tract symptoms. Saw palmetto (Serenoa
repens) fruit extract is a popular treatment. A 2002 Cochrane meta-analysis
concluded that saw palmetto extract is efficacious for improving BPH-related
lower urinary tract symptoms of nocturia and reduced urine flow.1
However, a 2009 Cochrane meta-analysis including 9 new trials concluded that
saw palmetto extract was not efficacious for BPH-related lower urinary tract
symptoms.2 The largest placebo-controlled trial (n = 220 men), known
as the Saw Palmetto Treatment for Enlarged Prostates (STEP) study, concluded
that 320 mg daily of a saw palmetto carbon dioxide extract was not
significantly better than placebo.3 The purpose of the current
double-blind, multicenter, placebo-controlled, randomized study was to see if a
dose greater than that used in the STEP study would be efficacious.
In an attempt to make
the study more real-world, the enrollment criteria was broad. Participants were
recruited at 10 sites in the United States and 1 site in Canada. Men were
eligible if they were aged ≥ 45 years, had a peak uroflow rate of at least 4
mL/s, and an American Urological Association Symptom Index (AUASI) score of between
8 and 24 at 2 screening visits. Men were ineligible if they had prior invasive
treatment for BPH; recent treatment with an α-blocker, 5α-reductase inhibitor,
phytotherapy including saw palmetto extract, or other medications affecting
lower urinary tract symptoms; creatinine level > 2.0 mg/dL; liver function
test results > 3 times normal; coagulopathy or anticoagulation; recent
unstable medical conditions; neurological conditions affecting urination;
recent prostatitis or repeated urinary tract infections; prostate or bladder
cancer or a prostate-specific antigen (PSA) level of more than 10 μg/L; recent
or planned genitourinary instrumentation; severe incontinence; recent diuretic
initiation or dose change; or medical conditions likely to prevent completion.
Patients received placebo or a lipidic ethanolic extract of dried, ripe saw
palmetto berries (Prosta-Urgenin Uno capsules; Rottapharm/Madaus; Cologne,
Germany) of 320 mg/day, with a dose escalation to 640 mg/day at 24 weeks and
another dose escalation to 960 mg/day at 48 weeks. The placebo group also
received an escalation, but dummy capsules were used. The study was completed
at 72 weeks. The primary outcome measure was the change in AUASI score from
baseline to 72 weeks. Secondary outcome measures included global assessments of
improvement and satisfaction, the BPH Impact Index, quality of life as assessed
with the International Prostate Symptom Score, nocturia item from the AUASI,
peak uroflow, post-void residual volume, PSA level, indices of erectile and
ejaculatory function, the International Continence Society male Incontinence
Scale, the Jenkins Sleep Dysfunction Scale, and the National Institutes of
Health Chronic Prostatitis Symptom Index. Assessments were made at baseline and
12, 24, 36, 48, 60, and 72 weeks.
A total of 357
patients (mean age = 61 years) were randomized, and 306 patients completed the
entire study and were included in the analysis. The study was well-blinded,
with a similar number of patients responding that they thought they were taking
placebo/saw palmetto when they were actually taking the other treatment (P =
0.36).
The primary outcome
measure (the AUASI score) showed no greater improvement with saw palmetto
extract than with placebo (P = 0.22). In addition, there was no significant
difference using saw palmetto extract compared with placebo at any dose level. Further,
saw palmetto was not more efficacious than placebo on any of the secondary
outcome measures. An exploratory subgroup analysis stratified by race/ethnicity
and other baseline parameters such as symptom severity did not reveal any
clinically important responses compared with placebo. Aside from physical
injuries or trauma, there were no significant differences in adverse events (AEs)
between groups, at any dose.
The authors conclude
that this saw palmetto extract at doses up to 960 mg/day was not more effective
than placebo for treating lower urinary tract symptoms related to BPH or for
secondary symptoms. The strengths of the study were: (1) use of a
well-characterized product, (2) adequate sample size, (3) multicenter design to
increase generalizability, (4) adequate dose and duration of treatment (24
weeks at each dose level), (5) excellent adherence with study medication and
visits, (6) comprehensive outcome measures, and (7) adequate blinding. The
authors point out that earlier studies did not have all of these strengths. A
limitation of the study is that the results may not apply to other products.
However, there have been negative studies that use other products, so the
authors think that "it is increasingly unlikely a dose of some preparation
will be identified that is better than placebo." Nonetheless, since the
potential active components and mechanism(s) are not known, the best
preparation is uncertain.
This study was
conducted as part of an Investigational New Drug Application for the US Food
and Drug Administration. The drug company donating the product had a vested
interest that the results would be positive, even though they did not sponsor
the study financially. This adds to the credibility of the findings, since the
outcome was negative.
—Heather S. Oliff,
PhD
References
1Wilt
T, Ishani A, MacDonald R. Serenoa repens
for benign prostatic hyperplasia. Cochrane
Database Syst Rev. 2002;(3):CD001423.
2Tacklind
J, MacDonald R, Rutks I, Wilt TJ. Serenoa
repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009;(2):CD001423.
3Bent S, Kane C, Shinohara K, et al. Saw palmetto for
benign prostatic hyperplasia. N Engl J
Med. 2006;354(6):557-566.
|